In the past year, shares of Bellerophon have skyrocketed 441.3% against the industry’s 9.1% decline. Zacks Investment Research Image Source: Zacks Investment Research Bellerophon has a mixed ...

TARRYTOWN, N.Y. — As post-lunch drowsiness settled on an auditorium full of leaders from the drug development industry, Peter Fernandes, CEO of Bellerophon Therapeutics, seized the presentation ...